RVMD - Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 | Benzinga
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.
Details of the planned presentations are listed below:
Revolution Medicines Oral Presentations:
| Title: |
| Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex Inhibitor |
| Presenter: |
| John Knox, Ph.D. |
| Abstract Number: |
| ND03 |
| Session: |
| New Drugs on the Horizon: Part 1 |
| Date/Time: |
| 1:45 – 2:00 p.m. PT on April 7, 2024 |
| Title: |
| RMC-6236, a RAS(ON) Multi-Selective Tri-Complex Inhibitor |
| Presenter: |
| Elena Koltun, Ph.D., Wei Lin, M.D. |
| Session: |
| KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology |
| Date/Time: |
| 1:00 – 1:20 p.m. PT on April 9, 2024 |
| Title: |
| Combination of RAS(ON) G12C-Selective and Multi-Selective Tri-Complex Inhibitors Overcomes Resistance and Prolongs Durability in Preclinical Models of KRASG12C NSCLC |